Evolent Health, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-534.5M | $-61.6M | $-113.0M | $-19.2M | $-37.6M | $-334.2M | $-302.0M | $-52.7M |
| Depreciation & Amortization | $115.9M | $118.4M | $123.4M | $67.2M | $60.0M | $61.5M | $60.9M | $44.5M |
| Depreciation | $26.3M | $30.3M | $32.4M | $32.0M | $30.6M | $28.3M | $23.3M | $17.3M |
| Amortization | $89.6M | $88.1M | $91.0M | $35.2M | $29.4M | $32.3M | $37.1M | $27.2M |
| Stock-Based Compensation | $39.7M | $39.7M | $40.5M | $34.0M | $16.7M | $14.6M | $15.6M | $17.6M |
| Net Cash from Operating Activities | $38.8M | $18.8M | $142.6M | $-11.6M | $38.7M | $-16.2M | $-42.6M | $-20.7M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | $35.5M | $39.6M |
| Business Acquisitions | $57.4M | $30.7M | $388.2M | $248.1M | $49.0M | $300.0K | $8.6M | $130.2M |
| Net Cash from Investing Activities | $-233.0K | $-62.9M | $-415.5M | $-259.1M | $-15.8M | $261.1M | $-181.6M | $-160.4M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $40.0M | $0 | $0 | — | — | — | — | — |
| Net Cash from Financing Activities | $-35.9M | $-565.0K | $281.3M | $131.5M | $-29.5M | $-11.9M | $-35.5M | $274.0M |
| Net Change in Cash | $2.2M | $-45.0M | $8.3M | $-139.8M | $-6.6M | $233.1M | $-259.8M | $93.0M |
| Free Cash Flow | — | — | — | — | — | — | $-78.2M | $-60.2M |